
Sign up to save your podcasts
Or


Blunt Business speaks with Dr. Benjamin Caplan, a distinguished family medicine doctor and member of the American Medical Association, who has overseen the healthcare journey of over 250,000 patients exploring the benefits of medical cannabis. Dr. Caplan recently published "The Doctor-Approved Cannabis Handbook," delving into the safe use of cannabis for managing various conditions like cognitive decline, cancer, chronic pain, depression, diabetes, insomnia, and headaches. Discover the effort behind building this comprehensive guide and gain valuable insights into incorporating cannabis treatment into everyday health.
Learn about the recent scientific review recommending the reclassification of marijuana from Schedule I to Schedule III, potentially opening new medical possibilities. Dr. Caplan shares his perspective on the implications this could have, including the potential end of IRS Section 280e restrictions.
Addressing federal scientists catching up with medical knowledge, Dr. Caplan reflects on whether the recent conclusions align with what doctors have known for years. Finally, hear Dr. Caplan's response to criticisms highlighted by The New York Times, addressing concerns about the strength and frequency of marijuana use, its ties to psychiatric problems, and the evolving landscape of therapeutic claims.
By Cannabis Radio4.1
3939 ratings
Blunt Business speaks with Dr. Benjamin Caplan, a distinguished family medicine doctor and member of the American Medical Association, who has overseen the healthcare journey of over 250,000 patients exploring the benefits of medical cannabis. Dr. Caplan recently published "The Doctor-Approved Cannabis Handbook," delving into the safe use of cannabis for managing various conditions like cognitive decline, cancer, chronic pain, depression, diabetes, insomnia, and headaches. Discover the effort behind building this comprehensive guide and gain valuable insights into incorporating cannabis treatment into everyday health.
Learn about the recent scientific review recommending the reclassification of marijuana from Schedule I to Schedule III, potentially opening new medical possibilities. Dr. Caplan shares his perspective on the implications this could have, including the potential end of IRS Section 280e restrictions.
Addressing federal scientists catching up with medical knowledge, Dr. Caplan reflects on whether the recent conclusions align with what doctors have known for years. Finally, hear Dr. Caplan's response to criticisms highlighted by The New York Times, addressing concerns about the strength and frequency of marijuana use, its ties to psychiatric problems, and the evolving landscape of therapeutic claims.

78,475 Listeners

25 Listeners

595 Listeners

10 Listeners

9 Listeners

120 Listeners

14 Listeners

20 Listeners

15 Listeners

42 Listeners

56,514 Listeners

707 Listeners

5 Listeners

10,242 Listeners

115 Listeners

53 Listeners

86 Listeners

12 Listeners

17,733 Listeners

133 Listeners

9,995 Listeners

129 Listeners

109 Listeners

14 Listeners